Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jun 24

PMID 35740594

Authors

Qianyu Wang

Xiaofei Shen

Gang Chen

Junfeng Du

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is one of the leading causes of death worldwide. The 5-year survival rate is 90% for patients with early CRC, 70% for patients with locally advanced CRC, and 15% for patients with metastatic CRC (mCRC). In fact, most CRC patients are at an advanced stage at the time of diagnosis. Although chemotherapy, molecularly targeted therapy and immunotherapy have significantly improved patient survival, some patients are initially insensitive to these drugs or initially sensitive but quickly become insensitive, and the emergence of such primary and secondary drug resistance is a significant clinical challenge. The most direct cause of resistance is the aberrant anti-tumor drug metabolism, transportation or target. With more in-depth research, it is found that cell death pathways, carcinogenic signals, compensation feedback loop signal pathways and tumor immune microenvironment also play essential roles in the drug resistance mechanism. Here, we assess the current major mechanisms of CRC resistance and describe potential therapeutic interventions.

Citing Articles

Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.

Haynes J, Manogaran P Int J Mol Sci. 2025; 26(5).

PMID: 40076613 PMC: 11901061. DOI: 10.3390/ijms26051988.

FAM50A as a novel prognostic marker modulates the proliferation of colorectal cancer cells via CylinA2/CDK2 pathway.

Li L, Ji Z, Li G, Gu H, Sun Y PLoS One. 2025; 20(2):e0318776.

PMID: 39999107 PMC: 11856281. DOI: 10.1371/journal.pone.0318776.

Colorectal Cancer: Current and Future Therapeutic Approaches and Related Technologies Addressing Multidrug Strategies Against Multiple Level Resistance Mechanisms.

Puzzo M, De Santo M, Morelli C, Leggio A, Catalano S, Pasqua L Int J Mol Sci. 2025; 26(3).

PMID: 39941081 PMC: 11818749. DOI: 10.3390/ijms26031313.

Enhancing chemoimmunotherapy for colorectal cancer with paclitaxel and alantolactone via CD44-Targeted nanoparticles: A STAT3 signaling pathway modulation approach.

Wu F, An X, Li S, Qiu C, Zhu Y, Ye Z Asian J Pharm Sci. 2025; 20(1):100993.

PMID: 39917727 PMC: 11795048. DOI: 10.1016/j.ajps.2024.100993.

Investigation of Exome-Wide Tumor Heterogeneity on Colorectal Tissue-Based Single Cells.

Szakallas N, Kalmar A, Bartak B, Nagy Z, Valcz G, Linkner T Int J Mol Sci. 2025; 26(2).

PMID: 39859451 PMC: 11766235. DOI: 10.3390/ijms26020737.

References

Song M, Li Z, Gu H, Tang R, Zhang R, Zhu Y . Spore Polysaccharide Inhibits the Growth of Hepatocellular Carcinoma Cells by Altering Macrophage Polarity and Induction of Apoptosis. J Immunol Res. 2021; 2021:6696606. PMC: 7954632. DOI: 10.1155/2021/6696606. View

Hecht J, Mitchell E, Neubauer M, Burris 3rd H, Swanson P, Lopez T . Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res. 2010; 16(7):2205-13. DOI: 10.1158/1078-0432.CCR-09-2017. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Chen M, Sharma A, Lin Y, Wu Y, He Q, Gu Y . Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells. BMC Cancer. 2019; 19(1):153. PMC: 6377751. DOI: 10.1186/s12885-019-5364-3. View

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J . Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011; 3(99):99ra86. PMC: 3268675. DOI: 10.1126/scitranslmed.3002442. View

Du J, He Y, Li P, Wu W, Chen Y, Ruan H . IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1). Cancer Chemother Pharmacol. 2018; 81(6):1111-1119. DOI: 10.1007/s00280-018-3584-x. View

Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z . lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat Med. 2017; 23(11):1331-1341. PMC: 5961502. DOI: 10.1038/nm.4424. View

Fujii R, Seshimo A, Kameoka S . Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol. 2003; 8(2):72-8. DOI: 10.1007/s101470300013. View

Ma X, Wang S, Ye Y, Du R, Cui Z, Somsouk M . Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol. 2004; 10(11):1569-73. PMC: 4572756. DOI: 10.3748/wjg.v10.i11.1569. View

10.

Ezzeldin H, Lee A, Mattison L, Diasio R . Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res. 2005; 11(24 Pt 1):8699-705. DOI: 10.1158/1078-0432.CCR-05-1520. View

11.

Xiao Q, Wu J, Wang W, Chen S, Zheng Y, Yu X . DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med. 2018; 24(3):262-270. PMC: 5840007. DOI: 10.1038/nm.4496. View

12.

Gyrd-Hansen M, Meier P . IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer. 2010; 10(8):561-74. DOI: 10.1038/nrc2889. View

13.

Liu L, Mayes P, Eastman S, Shi H, Yadavilli S, Zhang T . The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015; 21(7):1639-51. DOI: 10.1158/1078-0432.CCR-14-2339. View

14.

Zhang X, Chen Y, Hao L, Hou A, Chen X, Li Y . Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine. Cancer Lett. 2016; 381(2):305-13. DOI: 10.1016/j.canlet.2016.08.004. View

15.

Humeniuk R, Menon L, Mishra P, Gorlick R, Sowers R, Rode W . Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther. 2009; 8(5):1037-44. DOI: 10.1158/1535-7163.MCT-08-0716. View

16.

de Man F, Goey A, van Schaik R, Mathijssen R, Bins S . Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet. 2018; 57(10):1229-1254. PMC: 6132501. DOI: 10.1007/s40262-018-0644-7. View

17.

Liu R, Li J, Xie K, Zhang T, Lei Y, Chen Y . FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res. 2013; 73(19):5926-35. DOI: 10.1158/0008-5472.CAN-12-4718. View

18.

Fend L, Yamazaki T, Remy C, Fahrner C, Gantzer M, Nourtier V . Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. Cancer Res. 2017; 77(15):4146-4157. DOI: 10.1158/0008-5472.CAN-16-2165. View

19.

Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E . In search of definitions: Cancer-associated fibroblasts and their markers. Int J Cancer. 2019; 146(4):895-905. PMC: 6972582. DOI: 10.1002/ijc.32193. View

20.

Xian C . Roles of epidermal growth factor family in the regulation of postnatal somatic growth. Endocr Rev. 2007; 28(3):284-96. DOI: 10.1210/er.2006-0049. View